Immuron Limited — FY2023 Form 20-F
Reporting period: Fiscal year ended June 30, 2023. Although the request metadata refers to “2022 Q4,” this filing is an annual report for FY2023, not a standalone quarterly report. Financial amounts below are in Australian dollars (A$), unless stated otherwise. The consolidated statements are prepared under IFRS.
Business context
Immuron is an Australian commercial- and clinical-stage biopharmaceutical company developing orally delivered polyclonal antibodies from hyperimmune bovine colostrum. Its marketed products are Travelan, sold in Australia, the U.S. and Canada, and Protectyn, sold in Australia. Its principal development programs target travelers’ diarrhea/ETEC, Campylobacter infections and recurrent C. difficile infection (CDI).
Key financial results
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | A$1.805m | A$0.765m | Up 136% |
| Gross profit / margin | A$1.309m / 73% | A$0.524m / 68% | Margin increased |
| Other income, including R&D incentives and grants | A$2.591m | A$0.958m | Up A$1.634m |
| Operating loss | A$3.569m | A$2.870m | Loss widened |
| Net loss | A$3.787m | A$2.854m | Loss widened 33% |
| Basic/diluted loss per share | A$0.0166 | A$0.0125 | Loss per share increased |
| Net cash used in operating activities | A$2.595m | A$3.148m | Outflow reduced |
| Cash and cash equivalents at year-end | A$17.160m | A$22.110m | Down A$4.951m |
Sales growth reflected recovery in Travelan and Protectyn markets as travel resumed. FY2023 revenue comprised A$1.101m Travelan sales in Australia, A$0.643m in the U.S., A$0.001m in Canada, and A$0.060m Protectyn sales in Australia. The filing says the higher gross margin reflected higher selling prices.
Total operating expenses rose to A$7.740m from A$4.599m. R&D expense increased to A$2.592m from A$0.658m as development activity restarted after pandemic-related delays; selling and marketing expense rose to A$0.927m from A$0.417m, and general and administrative expense rose to A$4.221m from A$3.524m. The A$2.591m of other income included A$2.159m of MTEC grant income and A$0.393m of Australian R&D tax incentive income.
Balance sheet, cash flow and liquidity
At June 30, 2023, total assets were A$21.988m, total liabilities A$2.371m and net assets A$19.617m. Cash was A$17.160m. Current assets were A$20.409m and current liabilities A$2.219m. The filing reports no credit facilities and no contingent liabilities or commitments at year-end; lease liabilities were A$0.189m. Management stated that available cash was expected to fund capital requirements for at least 12 months from the financial statements’ issuance date and that the company could meet obligations as they fell due.
Operating cash outflow was A$2.595m. Investing cash outflow was A$2.621m, principally A$2.730m paid for the Ateria Health investment, partly offset by interest received. Financing cash outflow was A$0.045m, mainly lease principal and interest payments. Cash declined by A$4.951m after exchange-rate effects.
Material changes, unusual items and developments
- Travelan and Protectyn global sales were reported at A$1.805m, up 136% from FY2022, while sales remained below pre-pandemic levels. Management anticipated continued sales growth as travel increased.
- FY2023 included a A$0.431m inventory-provision writeback attributed to improved sales expectations. Inventory totaled A$2.060m; valuation was a critical audit matter because of shelf-life and sales-forecast judgments.
- Immuron invested A$2.651m for an initial 17.5% interest in UK-based Ateria Health. It recognized a A$0.524m fair-value loss on Ateria options and a A$0.324m share of associate losses. The option to acquire additional Ateria shares expired July 31, 2023 and was not exercised.
- Travelan’s FDA IND for a dose-optimization human challenge study was approved in December 2022. The first 30-person cohort was reported enrolled as of July 25, 2023, after year-end; results are intended to inform later pivotal studies. A separate 868-participant field trial had revised enrollment and completion estimates extending into 2024.
- The FDA lifted the clinical hold on the Campylobacter/ETEC investigational product in May 2023. The filing described first clinical studies as planned, not completed.
- For IMM-529, the company planned an FDA IND and a 60-patient study focused on recurrent CDI; protocol and site planning were ongoing. The earlier Israel study had been closed after only 9 of 60 planned patients were randomized. Management’s regulatory consultants considered orphan-drug designation challenging based on available data.
- Immuron deprioritized SARS-CoV-2 research in August 2022 to focus on more advanced programs. Earlier IMM-124E studies for NASH, severe alcoholic hepatitis and pediatric NAFLD did not show the intended clinical benefit; the company discontinued development for those indications.
Outlook, risks and contingencies
Management’s strategy is to grow sales of existing products while funding clinical development, including through government grants, collaborations, licensing, strategic alliances or capital raising. The company expects ongoing losses and states it may need additional funding for longer-term objectives; future funding is not assured and equity financing could dilute shareholders. No dividend was declared, and none is anticipated in the foreseeable future.
Key risks include uncertain clinical efficacy, enrollment, timing and regulatory approval; dependence on third-party trial organizations and manufacturers, including a sole manufacturer for the lead compound and reliance on contract manufacturers; uncertain commercial acceptance and reimbursement; competition; intellectual-property protection; and reliance on Australian R&D incentives and grant funding. Foreign-exchange exposure, particularly to the U.S. dollar, is not hedged. The auditor issued an unmodified opinion on the IFRS financial statements and identified inventory valuation and the Ateria investment as critical audit matters. Management assessed disclosure controls and internal control over financial reporting as effective at June 30, 2023.
Important facts for investors to verify
- Reconcile reported sales growth and geographic/product mix with subsequent-period sales, channel performance and customer concentration; four customers accounted for A$1.552m of FY2023 revenue.
- Track cash burn against management’s stated 12-month funding horizon, including clinical-trial spending, grant receipts and any additional financing plans.
- Confirm clinical-trial milestones and results for Travelan, the Campylobacter/ETEC program and IMM-529; distinguish completed events from plans and post-year-end updates.
- Review the assumptions behind the A$0.431m inventory-provision writeback, inventory shelf life and forecast sales, as well as the Ateria contingent consideration and investment valuation.
- Check the conditions, timing and eligibility of MTEC and Australian R&D incentive receipts, and whether grant income remains aligned with related project expenditure.
- Assess potential dilution from outstanding options, warrants and performance rights, and the effect of foreign-exchange movements on U.S.-dollar cash and reported results.